Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Immunic Inc

IMUX ✓ COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: STRONG BUY

Last Close

$16.06

▼ -3.14%

Market Cap $219.13M · Vol 18.33K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$219.13M

Micro Cap

Div Yield

N/A

EPS Growth

+29.06%

YoY

RSI (14)

69.04

Momentum

Beta

1.42

vs Market

52W High

$16.84

4.63% below

52W Low

$5.08

216.08% above

Volume

18.33K

Avg 45.16K

P/B

N/A

Price-to-book

ROE

N/A

Return on equity

Free Float

99.03%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Immunic Inc (IMUX) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does IMUX pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+12.31%

+9.33%

+26.91%

+76.00%

YTD

+200.92%

+75.23%

-6.08%

-83.02%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-97,172,000.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	N/A
ROA · ROIC	-299.36% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	N/A
P/FCF	N/A
EPS Growth	+29.06%
Outstanding Shares	13.64M

Technical Indicators

50-Day SMA	$14.42
200-Day SMA	$10.42
RSI (14)	69.04
Beta	1.42
52-Week High	$16.84
52-Week Low	$5.08

Volume Today	18.33K
Avg Daily Volume (30D)	45.16K
Relative Volume	0.41x
Volatility (10D)	55.16
Volatility (30D)	52.05
Free Float	99.03%

Analyst Consensus

STRONG BUY

Current Price $16.06

Mean Target $41.90

52W Low$5.08 52W High$16.84

Current

Target

$5.08 $16.84

Current Analyst target

+160.90% upside potential · 10 analysts

Identifiers

ExchangeNasdaq

FIGIBBG001V10N36

ISINUS4525EP2001

CountryUnited States of America

Sub-IndustryBio Therapeutic Drugs

Earnings DateNov 10, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co Ltd -2.85% ARGX.BR argenx SE -3.21% ARGX argenx SE -0.66% INSM Insmed Inc -2.05% 2269.HK WuXi Biologics (Cayman) Inc -1.27%

Company Profile

Immunic, Inc. is a biotechnology company developing a clinical pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases. The Company is engaged in pursuing clinical development of programs, which include the vidofludimus calcium (IMU-838) program, which is in Phase III clinical development for patients with relapsing multiple sclerosis (RMS), and which has shown therapeutic activity in Phase II clinical trials in patients suffering from relapsing-remitting MS, progressive MS and moderate-to-severe ulcerative colitis; the IMU-856 program, which is targeted to regenerate bowel epithelium and restore intestinal barrier function, which could potentially be applicable in numerous gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, Graft-versus-Host-Disease and weight management, and the IMU-381 program, which is a molecule being developed to specifically address the needs of gastrointestinal diseases.